The following link shows the commercial potential of PCSK9 inhibitors, with FDA-approved injectable drugs Repatha and Praluent expected to each generate sales of $1 Billion per year by 2020.
https://www.drugs.com/slideshow/pcsk9-inhibitors-a-new-option-in-cholesterol-treatment-1166
No one has been able to produce an oral drug that effectively binds to PCSK9 - until now.
PCSK9 has been validated as a cholesterol-lowering target, so how much might an oral inhibitor be worth to Big Pharma? I think I've said this before, but it is worth repeating: a Licence deal for NYX-330 would be worth about $5.00 per NOX share for each $1 Billion Big Pharma is willing to pay.
Nyrada is a hidden gem that is not reflected at all in the NOX share price, in my view.
NYX-330
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 52445 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 14000 | 1 |
View Market Depth
| Last trade - 16.00pm 27/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable
